Stable Angina Management Market Snapshot (2023 to 2033)

The global Stable Angina Management Market is expected to garner a market value of US$ 11 Billion in 2023 and is expected to accumulate a market value of US$ 25.1 Billion by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for Stable Angina Management registered a CAGR of 5.2% in the historical period 2018 to 2022.

Pharmaceutical products commonly used for the treatment of stable angina include antiplatelet agents, such as aspirin and clopidogrel, and nitroglycerin, which helps to relax and widen blood vessels. Beta-blockers, calcium channel blockers, and ACE inhibitors may also be prescribed to manage stable angina.

Medical devices used for the management of stable angina include stents, which are small mesh tubes that are inserted into narrowed or blocked arteries to improve blood flow, and coronary artery bypass surgery (CABG), which involves rerouting blood flow around a blocked or narrowed artery.

The stable angina management market is driven by factors such as the growing prevalence of cardiovascular diseases, increasing adoption of advanced medical technologies, and rising healthcare expenditure. However, the market may face challenges such as the availability of alternative treatment options, high cost of some treatments, and limited access to healthcare in certain regions.

Report Attribute Details
Expected Market Value (2023) US$ 11 Billion
Anticipated Forecast Value (2033) US$ 25.1 Billion
Projected Growth Rate (2023 to 2033) 8.6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Stable Angina Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Stable Angina Management reflected a value of 5.2% during the historical period, 2018 to 2022. The stable angina management market is expected to grow in the coming years due to various factors such as the rising prevalence of cardiovascular diseases, increasing demand for effective treatment options, and the adoption of advanced medical technologies.

The increasing prevalence of cardiovascular diseases and the growing geriatric population are expected to be the major driving factors for the market's growth. Moreover, the increasing adoption of innovative technologies such as drug-eluting stents, bioresorbable stents, and optical coherence tomography (OCT) for the diagnosis and treatment of stable angina is expected to drive market growth. The increasing demand for minimally invasive procedures is also expected to drive the market's growth as they offer less discomfort, shorter recovery times, and lower healthcare costs compared to traditional open-heart surgeries.

Overall, the market for Stable Angina Management is expected to register a CAGR of 8.6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Stable Angina Management Market?

Increasing Prevalence of Cardiovascular Diseases to Push Market Growth

The rising prevalence of cardiovascular diseases is expected to be one of the major drivers pushing the growth of the stable angina management market. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, and they are among the leading causes of death and disability worldwide. Stable angina is one of the most common forms of CVDs.

According to a report by the World Health Organization (WHO), CVDs are the leading cause of death globally, with an estimated 17.9 million deaths annually. The report also highlights that four out of five CVD deaths are due to heart attacks and strokes, which are often caused by a blockage that prevents blood flow to the heart or brain.

As the prevalence of CVDs continues to rise globally, the demand for effective treatment options for stable angina is also expected to increase. This is likely to drive the growth of the stable angina management market, as more patients seek medical interventions to manage their condition.

Moreover, the increasing incidence of risk factors for CVDs, such as high blood pressure, high cholesterol, obesity, and diabetes, is also contributing to the rise in CVDs. This is expected to further increase the demand for stable angina management products and services.

Overall, the rising prevalence of CVDs, along with increasing awareness and a growing demand for effective treatment options, is expected to push the growth of the stable angina management market in the coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Stable Angina Management Market?

Expensive Cost of Treatment to restrict Market Growth

The high cost of treatment is a major challenge for the stable angina management market. The cost of diagnostic tests, medications, and procedures can be prohibitively expensive, especially for patients in developing countries. This can limit access to treatment options and hinder market growth.

The regulatory environment can also pose challenges to the stable angina management market. The approval process for new medical devices and treatments can be lengthy and expensive, and regulatory requirements can vary from country to country. Overall, while the stable angina management market has significant growth potential, it also faces several challenges that need to be addressed to ensure sustained growth and development.

Region-Wise Insights

How is the Stable Angina Management Market Turning Out in the South & East Asia Region?

Increasing awareness and diagnosis of the condition Shaping Landscape for Stable Angina Management in South & East Asia

One of the major drivers of the market growth in the region is the increasing prevalence of cardiovascular diseases, including stable angina. The rising incidence of risk factors such as obesity, high blood pressure, and diabetes, coupled with lifestyle changes, is contributing to the growing burden of cardiovascular diseases in the region.

Another factor contributing to the market growth is the increasing adoption of advanced medical technologies for the diagnosis and treatment of stable angina. The region has witnessed significant investments in the development of innovative medical devices and therapies, which are expected to drive market growth.

Moreover, the increasing healthcare expenditure by governments and private organizations in the region is expected to fuel the market's growth. Governments in the region are investing heavily in the development of healthcare infrastructure, which is expected to improve access to healthcare services for the population.

Overall, the stable angina management market in the South & East Asia region is expected to grow in the coming years, driven by the increasing prevalence of cardiovascular diseases and the adoption of advanced medical technologies. However, addressing the challenges and improving access to healthcare services and treatments will be critical for sustained market growth.

What are the Factors Boosting the Market for Stable Angina Management in North America?

Increasing Focus on Technological advancements Shaping Landscape for Stable Angina Management in North America

The market for Stable Angina Management in North America is expected to grow due to several factors. The North American region has a high prevalence of cardiovascular diseases, including stable angina. According to the American Heart Association, cardiovascular diseases are the leading cause of death in the United States, with approximately 18.6 million adults diagnosed with coronary heart disease. The high prevalence of cardiovascular diseases is expected to drive the demand for stable angina management products and services in the region.

Secondly, the North American region is at the forefront of technological advancements in the healthcare sector. The development of advanced medical devices and therapies, such as drug-eluting stents, implantable cardioverter-defibrillators, and transcatheter aortic valve replacement (TAVR), has improved the diagnosis and treatment of stable angina. These advancements are expected to drive market growth in the region.

North America has one of the highest healthcare expenditures in the world. According to the Centers for Medicare & Medicaid Services (CMS), national health expenditures in the United States reached $3.8 trillion in 2019, accounting for 17.7% of the country's GDP. The high healthcare expenditure is expected to drive market growth as it improves access to healthcare services and treatments for patients with stable angina.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies segment to hold a significant share and push market growth

Hospital pharmacies are the primary distribution channels for stable angina management products and services. They have access to a wide range of products, including prescription drugs, medical devices, and surgical instruments, and they are well-equipped to handle complex patient cases. In addition, hospital pharmacies have the advantage of being able to provide patients with a range of healthcare services, including consultation with healthcare professionals, medication counseling, and monitoring of medication adherence.

Moreover, the hospital pharmacies segment is expected to grow due to the increasing number of hospital admissions for cardiovascular diseases, including stable angina. Hospitals are the primary point of care for patients with cardiovascular diseases, and they play a critical role in managing the disease and preventing complications. As a result, hospital pharmacies are likely to account for a significant share of the stable angina management market.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.

  • In Early 2022, Health Canada granted approval for Corzyna as an additional therapy for patients suffering from stable angina who do not respond well to or cannot tolerate first-line therapies. Corzyna is considered a second-line therapy and is more expensive than the current treatment options for angina, with an annual cost of $2,555. This medication is recommended to be placed under Special Authorization for ClaimSecure groups subscribing to Managed Plans to ensure it is reserved for patients who have tried or are intolerant to more cost-effective options, while it will be fully covered for groups subscribing to Open Formularies.

Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 11 Billion
Market Value in 2033 US$ 25.1 Billion
Growth Rate CAGR of 8.6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Distribution Channel
  • Drug Class
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Malaysia
  • Singapore
  • China
  • India
  • Thailand
  • Rest of South Asia
  • Gulf Cooperation Council
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc.
Customization Available Upon Request

Key Segments Profiled in the Stable Angina Management Industry Survey

Drug Class:

  • Beta Blockers
  • Calcium Antagonists
  • Anti-coagulants
  • Antiplatelets

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

At what rate did the Stable Angina Management Market flourish from 2018 to 2022?

From 2018 to 2022, Stable Angina Management Market grew at a CAGR of 5.2%.

What will be the growth rate of the global Stable Angina Management Market during the forecast period?

The global Stable Angina Management Market is expected to grow with a 8.6% CAGR during 2023 to 2033.

What will be the projected market size of the Stable Angina Management Market by 2033?

As of 2033, the Stable Angina Management Market is expected to reach US$ 25.1 Billion

Which segment of the Distribution Channel is expected to dominate the global Stable Angina Management Market during 2033?

According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.

How is the North America Stable Angina Management Market projected to grow in 2033?

North America is expected to possess 40% market share for the Stable Angina Management Market.

How Big is the Market in 2023? 

The market is valued at US$ 11.0 billion in 2023. 

Who are the Key Market Players? 

Abbott, AstraZeneca, and Bayer AG are the key market players. 

How was the Historical Performance of the Market? 

The market registered a CAGR of 5.2% from 2018 to 2022.

What Opportunities Await the Market Players? 

Rising cases of cardiovascular diseases globally boost the market growth.

Which is the Key Segment by Distribution Channel? 

The hospital pharmacies segment is likely to remain preferred through 2033. 

Table of Content

1. Executive Summary | Stable Angina Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Beta Blockers

        5.3.2. Calcium Antagonists

        5.3.3. Anti-coagulants

        5.3.4. Anti-Platelets

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Online pharmacies

        6.3.2. Hospital pharmacies

        6.3.3. Retail pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distribution Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distribution Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distribution Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distribution Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distribution Channel

    15.6. United kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distribution Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distribution Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distribution Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distribution Channel

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distribution Channel

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distribution Channel

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distribution Channel

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distribution Channel

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distribution Channel

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distribution Channel

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distribution Channel

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distribution Channel

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distribution Channel

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distribution Channel

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distribution Channel

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distribution Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Abbott

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. AstraZeneca

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Bayer AG

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Bristol-Myers Squibb Company

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. F. Hoffmann-La Roche Ltd

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. ALLERGAN

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Gilead Sciences, Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. GlaxoSmithKline plc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Novartis AG

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Pfizer Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Angiogenesis Assays Market

July 2023

REP-GB-10030

250 pages

Healthcare

Unstable Angina Therapeutics Market

January 2023

REP-GB-16605

299 pages

Healthcare

Prinzmetal Angina Therapeutics Market

January 2023

REP-GB-16366

300 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Stable Angina Management Market

Schedule a Call